|
1
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhao H, Dong Z, Wan D, Cao W, Xing H, Liu
Z, Fan J, Wang H, Lu R, Zhang Y, et al: Clinical characteristics,
treatment, and prognosis of 118 cases of myeloid sarcoma. Sci Rep.
12:67522022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Almond LM, Charalampakis M, Ford SJ,
Gourevitch D and Desai A: Myeloid sarcoma: Presentation, diagnosis,
and treatment. Clin Lymphoma Myeloma Leuk. 17:263–267. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mandhan N, Yassine F, Li K and Badar T:
Bladder myeloid sarcoma with TP53 mutated myelodysplastic
syndrome/myeloproliferative neoplasm overlap syndrome: Response to
Decitabine-Venetoclax regimen. Leuk Res Rep.
17:1002862021.PubMed/NCBI
|
|
5
|
Bakst RL, Tallman MS, Douer D and Yahalom
J: How I treat extramedullary acute myeloid leukemia. Blood.
118:3785–3793. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kaur V, Swami A, Alapat D, Abdallah AO,
Motwani P, Hutchins LF and Jethava Y: Clinical characteristics,
molecular profile and outcomes of myeloid sarcoma: A single
institution experience over 13 years. Hematology. 23:17–24. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ganzel C, Manola J, Douer D, Rowe JM,
Fernandez HF, Paietta EM, Litzow MR, Lee JW, Luger SM, Lazarus HM,
et al: Tallman, Extramedullary disease in adult acute myeloid
leukemia is common but lacks independent significance: Analysis of
patients in ECOG-ACRIN cancer research group trials, 1980–2008. J
Clin Oncol. 34:3544–3553. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang HQ and Li J: Clinicopathological
features of myeloid sarcoma: Report of 39 cases and literature
review. Pathol Res Pract. 212:817–824. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Toguchida J, Yamaguchi T, Ritchie B,
Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki
MS and Little JB: Mutation spectrum of the p53 gene in bone and
soft tissue sarcomas. Cancer Res. 52:6194–6199. 1993.PubMed/NCBI
|
|
10
|
Thoenen E, Curl A and Iwakuma T: TP53 in
bone and soft tissue sarcomas. Pharmacol Ther. 202:149–164. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ortiz-Cuaran S, Cox D, Villar S, Friesen
MD, Durand G, Chabrier A, Khuhaprema T, Sangrajrang S, Ognjanovic
S, Groopman JD, et al: Association between TP53 R249S mutation and
polymorphisms in TP53 intron 1 in hepatocellular carcinoma. Genes
Chromosomes Cancer. 52:912–919. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Welch JS, Petti AA, Miller CA, Fronick CC,
O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon
B, et al: TP53 and Decitabine in acute myeloid leukemia and
Myelodysplastic Syndromes. N Engl J Med. 375:2023–2036. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang J and Yang L, Yang B, Tian Y, Ren J
and Yang L: Clinical characteristics, treatment options, and
prognosis of myeloid sarcoma: Analysis using the SEER database.
Hematology. 28:22478982023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gajendra S, Goel S, Sharma R, Dhiman P and
Sachdev R: Myeloid sarcoma presented as generalized
lymphadenopathy: Mimicking malignant lymphoma. Indian J Hematol
Blood Transfus. 34:173–177. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fang L, Hua C, Jie B, et al: A case of
gastric granulocytic sarcoma misdiagnosed as non Hodgkin's
lymphoma. Int J Lab Med. 37:3524–3526. 2016.(In Chinese).
|
|
16
|
Kawamoto K, Miyoshi H, Yoshida N, Takizawa
J, Sone H and Ohshima K: Clinicopathological, cytogenetic, and
prognostic analysis of 131 myeloid sarcoma patients. Am J Surg
Pathol. 40:1473–1483. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shallis RM, Gale RP, Lazarus HM, Roberts
KB, Xu ML, Seropian SE, Gore SD and Podoltsev NA: Myeloid sarcoma,
chloroma, or extramedullary acute myeloid leukemia tumor: A tale of
misnomers, controversy and the unresolved. Blood Rev.
47:1007732021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ray-Coquard I, Blay JY, Italiano A, Le
Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, et al:
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients
with MDM2-amplified, well-differentiated or dedifferentiated
liposarcoma: An exploratory proof-of-mechanism study. Lancet Oncol.
13:1133–1140. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gopalakrishnan V, Amini B, Wagner MJ,
Nowell EN, Lazar AJ, Lin PP, Benjamin RS and Araujo DM: Synovial
sarcoma of the head and neck: A single institution review. Sarcoma.
2017:20167522017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee JY, Chung H, Cho H, Jang JE, Kim Y,
Kim SJ, Kim JS, Hyun SY, Min YH and Cheong JW: Clinical
characteristics and treatment outcomes of isolated myeloid sarcoma
without bone marrow involvement: A single-institution experience.
Blood Res. 52:184–192. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Imrie KR, Kovacs MJ, Selby D, Lipton J,
Patterson BJ, Pantalony D, Poldre P, Ngan BY and Keating A:
Isolated chloroma: The effect of early antileukemic therapy. Ann
Intern Med. 123:351–353. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim K, Maiti A, Loghavi S, Pourebrahim R,
Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M,
et al: Outcomes of TP53-mutant acute myeloid leukemia with
decitabine and venetoclax. Cancer. 127:3772–3781. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hackanson B and Daskalakis M: Decitabine.
Recent Results Cancer Res. 201:269–297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gornicec M, Wolfler A, Stanzel S, Sill H
and Zebisch A: Evidence for a role of decitabine in the treatment
of myeloid sarcoma. Ann Hematol. 96:505–506. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Soussi T and Lozano G: p53 mutation
heterogeneity in cancer. Biochem Biophys Res Commun. 331:834–842.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goh AM, Xue Y, Leushacke M, Li L, Wong JS,
Chiam PC, Rahmat SA, Mann MB, Mann KM, Barker N, et al: Mutant p53
accumulates in cycling and proliferating cells in the normal
tissues of p53 R172H mutant mice. Oncotarget. 6:17968–17980. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Asada N, Tsuchiya H and Tomita K: De novo
deletions of p53 gene and wild-type p53 correlate with acquired
cisplatin-resistance in human osteosarcoma OST cell line.
Anticancer Res. 19:5131–5137. 1999.PubMed/NCBI
|
|
28
|
Liu Y, Hu X, Han C, Wang L, Zhang X, He X
and Lu X: Targeting tumor suppressor genes for cancer therapy.
Bioessays. 37:1277–1286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lane D and Levine A: p53 research: The
past thirty years and the next thirty years. Cold Spring Harb
Perspect Biol. 2:a0008932010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Al-Romaih K, Bayani J, Vorobyova J,
Karaskova J, Park PC, Zielenska M and Squire JA: Chromosomal
instability in osteosarcoma and its association with centrosome
abnormalities. Cancer Genet Cytogenet. 144:91–99. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zuffa E, Mancini M, Brusa G, Pagnotta E,
Hattinger CM, Serra M, Remondini D, Castellani G, Corrado P,
Barbieri E and Santucci MA: P53 oncosuppressor influences selection
of genomic imbalances in response to ionizing radiations in human
osteosarcoma cell line SAOS-2. Int J Radiat Biol. 84:591–601. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Martin JW, Squire JA and Zielenska M: The
genetics of osteosarcoma. Sarcoma. 2012:6272542012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Daver NG, Maiti A, Kadia TM, Vyas P,
Majeti R, Wei AH, Garcia-Manero G, Craddock C, Sallman DA and
Kantarjian HM: TP53-mutated myelodysplastic syndrome and acute
myeloid leukemia: Biology, current therapy, and future directions.
Cancer Discov. 12:2516–2529. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Olivier M, Hollstein M and Hainaut P: TP53
mutations in human cancers: Origins, consequences, and clinical
use. Cold Spring Harb Perspect Biol. 2:a0010082010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Middeke JM, Herold S, Rucker-Braun E,
Berdel WE, Stelljes M, Kaufmann M, Schäfer-Eckart K, Baldus CD,
Stuhlmann R, Ho AD, et al: TP53 mutation in patients with high-risk
acute myeloid leukaemia treated with allogeneic haematopoietic stem
cell transplantation. Br J Haematol. 172:914–922. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Veldore VH, Patil S, Satheesh CT,
Shashidhara HP, Tejaswi R, Prabhudesai SA, Krishnamoorthy N,
Hazarika D, Naik R, Rao RM and Kumar BS: Genomic profiling in a
homogeneous molecular subtype of non-small cell lung cancer: An
effort to explore new drug targets. Indian J Cancer. 52:243–248.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Haefliger S, Harder D, Kovac M,
Linkeschova K, Eufinger H and Baumhoer D: Osteosarcoma of the
mandible in a patient with Florid Cemento-Osseous Dysplasia and
Li-Fraumeni syndrome: A rare coincidence. Head Neck Pathol.
15:704–708. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pastoret C, Houot R, Llamas-Gutierrez F,
Boulland ML, Marchand T, Tas P, Ly-Sunnaram B, Gandemer V, Lamy T,
Roussel M and Fest T: Detection of clonal heterogeneity and
targetable mutations in myeloid sarcoma by high-throughput
sequencing. Leuk Lymphoma. 58:1008–1012. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kryczka J, Kryczka J, Czarnecka-Chrebelska
KH and Brzeziańska-Lasota E: Molecular mechanisms of
chemoresistance induced by cisplatin in NSCLC cancer therapy. Int J
Mol Sci. 22:88852021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xiangli L, Mingli Z, Jiao W, Jie C, Yu C,
Zhenyi N and Xuetao L: Expression and significance of PD-L1, Ki-67,
TP53, and EGFR in lung adenocarcinoma tissues. J Basic Clin Oncol.
36:324–327. 2023.(In Chinese).
|
|
41
|
Shen W, Xi H, Wei B and Chen L: The
prognostic role of matrix metalloproteinase 2 in gastric cancer: A
systematic review with meta-analysis. J Cancer Res Clin Oncol.
140:1003–1009. 2014.(In Chinese). View Article : Google Scholar : PubMed/NCBI
|
